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Optimal duration of chemotherapy in non-small-cell lung cancer: 
multicenter, randomized, prospective clinical trial comparing 4 vs 6 
cycles of carboplatin and gemcitabine
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Fernando3 Fernandes, Ana4 Cunha, João5 Araujo, Antonio6 Costa, 
Agostinho3 Valente, Lassalete7 
1 Grupo Estudo Cancro Pulmão, Coimbra, Portugal 2 GECP, Gaia, 
Portugal 3 GECP, Lisboa, Portugal 4 GECP, Vila Real, Portugal 5 
GECP, Braga, Portugal 6 GECP, Porto, Portugal 7 GECP, Covilhã, 
Portugal 
Background: So far there are few published data on optimal duration 
of chemotherapy in patients with advanced non small cell lung cancer 
(NSCLC) We designed a phase III trial to compare 4 cycles vs 6 cycles 
of chemotherapy using a standard combination. Primary endpoint is 
overall survival (OS). Secondary endpoints included time to progres-
sion (TPP), overall response rate (ORR), one-year survival (1y -S) and 
safety. 
Methods: Randomization was stratiﬁed by stage (IV vs IIIB) and per-
formance status (0/1 vs 2). Patients received gemcitabine 1250 mg/m2, 
day 1 and 8 + Carboplatin, AUC 5, day 1, every 21 days. Eligibility 
criteria: age > 18 years, histologically proven NSCLC, weight loss < 
10%, no brain metastasis, adequate renal, hematological, hepatic func-
tions and informed consent. The efﬁcacy analysis (OS, TTP, 1y-S) will 
be performed on intent to treat basis. 
Results: Between October 2002 and December 2004, 220 pts were 
enrolled. Arm A - 4 cycles (n=110) and Arm B - 6 cycles (n= 110) were 
well-balanced for patient characteristics: median age (A/B): 64,7 vs 
63,9 yrs; male/female (A/B) 86/24 vs 86/24; IIIB/IV (A/B) 24/86 vs 
29/81; PS 0,1 vs 2 (A/B) 90/20 vs 91/19; adenocarcinoma (A/B) 59 
vs 57; squamous (A/B) 35 vs 37. ORR and toxicity was evaluated in 
204 pts (7.2% pts were not evaluated). ORR% (43,8 vs 47,3); median 
number courses (3,5 vs 4,8). Grade 3/4 toxicities included neutropenia 
(10,2% vs 13,6%); thrombocytopenia (3.1% vs 5,2%); anemia (1,0% 
vs 2,1%). All grades of nausea/vomiting (14,2% vs 16,8%). Fifteen 
pts (Arm A) and sixteen pts (Arm B) have had a second line therapy 
(docetaxel) after disease progression. At Jan/2007, 107 at each arm 
died. Time to progression was not statistically different between the 
two treatment arms (p=0.077). Median time to progression was 4 
months (95% CI: 3.2-4.8 months) for patients randomized to 4 cycles 
and 5 months (95% CI: 3.8-6.2 months) for patients randomized to 
6 cycles. Overall survival was statistically different between the two 
treatment groups (p=0.047) and favourable to 6 cycles. Median survival 
was 7 months (95% CI: 5.9-8.1 months) for 4-cycles regimen and 12 
months (95% CI: 9.8-14.2 months) for 6-cycles regimen. When com-
pares patients according to the number of cycles they really received 
and according to the randomisation regimen assigned: 79 patients in 4 
cycles and 65 in 6 cycles. Time to progression and overall survival was 
statistically different between the two treatment groups (p=0.018) and 
favourable to the regimen of 6 cycles
Conclusions: Overall survival rate was statistically different between 
4 vs 6 cycles. TTP, ORR and One year survival was not statistically 
different. In patients without progression or major toxicity during che-
motherapy, we recommend six cycles in ﬁrst line chemotherapy.
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Phase II pharmacogenomic trial of IV vinorelbine (V), gemcitabine 
(G) and cisplatin (P) in advanced non-small-cell lung cancer 
(NSCLC). Preliminary results of efficacy and safety
Barneto, Isidoro1 Rueda, Antonio2 Bernabe, Reyes3 Medina, Begoña4 
Noguer, Manuel5 Montaño, Alvaro6 
1 Servicio de Oncologia Medica - Hospital Universitario Reina Sofia, 
Cordoba, Spain 2 Servicio de Oncologia Medica - Hospital Puerta del 
Mar, Cadiz, Spain 3 Servicio de Oncologia Medica - Hospital de Valme, 
Sevilla, Spain 4 Servicio de Oncologia Medica - Hospital de Jaen, Jaen, 
Spain 5 Servicio de Oncologia Medica - Hospital Universitario Virgen 
del Rocio, Sevilla, Spain 6 Servicio de Oncologia Medica - Hospital 
Juan Ramon Jimenez, Huelva, Spain 
Background: The combinations of cisplatin with vinorelbine or gem-
citabine are among the most active regimens for NSCLC. We evaluated 
vinorelbine/gemcitabine/cisplatin (VGP) in a phase II trial in advanced 
NSCLC. Data on thirty-seven evaluable patients (pts) is presented in 
this report. 
Methods: Pt characteristics: 92% stage IV, 8% stage IIIB; 100% 
ECOG 0-1; median age 61 years (42-77); 39,4% adenocarcinoma, 
48,5% epidermoid. Treatment was V 25 mg/m2 and G 1000 mg/m2, 
both drugs given on D1 and D8, followed by P 60 mg/m2 D1, every 3 
weeks for 6 cycles. 
Results: A total of 187 cycles were delivered (62.2% pts received 
6 cycles). Of 37 evaluable pts, 17 (45.9%, [95% CI, 29.5-63.1%]) 
achieved partial response. The median survival time is 9.3 months 
[95% CI, 6.0-12.5]. The median event free survival time is 7.3 months 
[95% CI, 5.7-8.9]. In terms of tolerance, grade (Gr) 3/4 neutropenia 
was observed in 13.9% of cycles (38.8% of pts); Gr 3/4 anemia in 3.7% 
(16.2% pts); Gr 3 fatigue in 3.2% (16.2% pts); Gr 3 vomiting in 1.6% 
(8.1% pts). No patient had lethal toxicity. 
Conclusions: The combination of vinorelbine, gemcitabine and cispla-
tin is active and tolerable in ﬁrst line NSCLC treatment, with reversible 
neutropenia as the major toxicity. Complete data on genetic markers 
will be presented.
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Pemetrexed as second-line treatment in advanced NSCLC patients: 
results on 160 patients in a multi-institutional analysis
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Adolfo3 Boccalon, Massimo4 Talamini, Renato5 Santoro, Armando2 
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Background: ASCO and NCCN guidelines recommend docetaxel, 
pemetrexed and erlotinib in the second-line setting for Non Small Cell 
Lung Cancer (NSCLC). In a large phase III trial docetaxel and peme-
trexed showed similar activity in this setting. On the basis of this trial, 
the FDA in the US and the EMEA in Europe approved Pemetrexed for 
second-line setting of NSCLC. Our aim was to check activity, feasibil-
ity and toxicity data of Pemetrexed as second or further line treatment 
in a post-registration phase.
Matherial and Methods: We collected data about patients affected 
by locally advanced or metastatic NSCLC from 4 Italian Institutions, 
consecutively treated with Pemetrexed 500 mg/sqm, q21 days, after 
